menu

Volanesorsen goes to the EMA for marketing authorisation

“Based on the positive results from the Phase 3 program with volanesorsen, I’m encouraged that for the first time, these patients may have a new therapy that can help them achieve the triglyceride reductions they need to lessen the burden of their disease and decrease their risk for pancreatitis.” Dr. Marcello Arca, Head of the […]
View this article

UK results of IN-FOCUS survey

“FCS impacts most areas of the life of someone who has it and those close to them. It affects everything from what they can eat to their relationships with their friends and family, their employment and their sense of self-worth,” says Jill Prawer, Chair of the LPLD Alliance. “FCS is often misunderstood and misdiagnosed, and […]
View this article

The End of Glybera

uniQure, the company that developed Glybera has made the decision not to pursue the renewal of its marketing authorization in Europe when it is scheduled to expire in October 25th of this year. That effectively means that the product will no longer be available commercially after that time. Please see the press release for futher […]
View this article
News archive